Tuesday, July 1, 2025 7/1/2025

Synthesis of Lipooligosaccharide-Capsular Polysaccharide Conjugates for the Prevention and Treatment of Infections Caused by Acinetobacter baumannii

Award Number: R15AI140226
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2019
PERIOD OF PERFORMANCE END DATE: 02/28/2023

Group Awards By:

View Award Description

Synthesis of Lipooligosaccharide-Capsular Polysaccharide Conjugates for the Prevention and Treatment of Infections Caused by Acinetobacter baumannii - The proposed work will involve the synthesis of molecules designed to trigger long-lived, adaptive immune responses that are protective against infection caused by the Gram-negative coccobacillus Acinetobacter baumannii. There are presently no approved vaccines for A. baumannii, and there has been an increasing incidence of infections caused by drug-resistant strains. Central Hypothesis: Covalent conjugation of synthetic portions of an Acinetobacter baumannii lipooligosaccharide (LOS) to the Bacteroides fragilis capsular polysaccharide A1 (PSA1) will result in molecules that can trigger adaptive immune responses selective to A. baumannii. Project Goals: Short-term goals include synthesis of A. baumannii LOS-PSA1 conjugates and their injection into mice to determine their efficacy in prevention of infections caused by A. baumannii. Long-term goals include the development of a vaccine and the development of monoclonal antibodies to be used as a therapeutic. Specific Aims: Specific Aim 1: Synthesis of A. baumannii LOS core oligosaccharides that can be conjugated to PSA1 and other carrier molecules. The success of this Specific Aim will lie in the effective implementation of synthetic strategies and completion of target molecules. Specific Aim 2: Conjugation of the A. baumannii LOS core oligosaccharides to PSA1 and subsequent injection into mice followed by studies to determine immunogenicity and protective effects against A. baumannii infection. The immunogenicity and protective effects of the LOS-PSA1 conjugates against bacterial challenge with A. baumannii will be studied. The success of this Specific Aim will lie in the effective protection of mice against infection by A. baumannii in which long-lived, adaptive immunity has been triggered. Specifc Aim 1 studies will involve the multistep chemical synthesis of a series of five oligosaccharides with varying complexity and which are based on an A. baumannii LOS core structure. The 4-aryl-3- butenylthioglycosides undergoing development in our laboratory will be critical intermediates in these syntheses. Other key features include synthetic strategies to generate an alkoxyamine-bearing linker that will be used to conjugate the oligosaccharides to PSA1. Specific Aim 2 studies will start with the condensation of the aforementioned alkoxyamine-bearing oligosaccharides with aldehydes generated through the oxidative cleavage of a diol moiety on PSA1. The resulting LOS-PSA1 conjugates will be injected into mice and the mouse anti-sera will be collected subsequently. The immunogenicity of the LOS-PSA1 conjugates will be determined through ELISA assays to determine the nature of the antibody response as well as flow cytometry to determine if the antibodies bind to A. baumannii in addition to an assay to determine the bactericidal effects of the sera. Pending the results of the initial serological experiments, bacterial challenge experiments in which bacterial dissemination and survival rates in mice are determined will be conducted. Such experiments will be conducted with the most promising LOS-PSA1 conjugates based on the initial serological experiments.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2019	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Allergy and Infectious Diseases Research	000	1	1/16/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $430,960 )
2019	2019	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Allergy and Infectious Diseases Research	001	1	3/11/2019	NEW	$0
2019	2019	LOUISIANA STATE UNIVERSITY	202 HIMES HALL	BATON ROUGE	LA	70803	EAST BATON ROUGE	USA	Allergy and Infectious Diseases Research	000	1	2/19/2019	NEW	$430,960
														Subtotal = $430,960

Grand Total All Awards = $430,960

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Synthesis of Lipooligosaccharide-Capsular Polysaccharide Conjugates for the Prevention and Treatment of Infections Caused by Acinetobacter baumannii

Award Number: R15AI140226

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2019

PERIOD OF PERFORMANCE END DATE: 02/28/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer